Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Abstract : Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS), Pegasys and PegIntron, BIND-014, CRLX-101, Oncaspar, Neulasta, Aurimmune, Auroshell, AuNPs, Nanotherm, NanoXray, Magnetosome chains, Kadcyla (T-DM1), Ontak (DAB/IL2), Gendicine and Curcumin. We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.
Type de document :
Article dans une revue
Expert Review of Anticancer Therapy, Expert Reviews (formerly Future Drugs), 2015, 15 (10), pp.1233 - 1255. 〈10.1586/14737140.2015.1086647〉
Liste complète des métadonnées

Littérature citée [134 références]  Voir  Masquer  Télécharger

https://hal.sorbonne-universite.fr/hal-01547085
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : lundi 26 juin 2017 - 13:21:22
Dernière modification le : mardi 29 mai 2018 - 12:50:22
Document(s) archivé(s) le : lundi 22 janvier 2018 - 17:40:24

Fichier

Alphandery_2015_Cancer_therapy...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Edouard Alphandéry, Pierre Grand-Dewyse, Raphael Lefèvre, Chalani Mandawala, Mickael Durand-Dubief. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Review of Anticancer Therapy, Expert Reviews (formerly Future Drugs), 2015, 15 (10), pp.1233 - 1255. 〈10.1586/14737140.2015.1086647〉. 〈hal-01547085〉

Partager

Métriques

Consultations de la notice

321

Téléchargements de fichiers

248